Clinical trials: Normal Skin
Actinic Keratosis
PEP005 Gel - Biological Effects in Actinic Keratosis Assessed by Reflectance Confocal Microscopy
This trial will be conducted to explore the biological effects in the skin following treatment with PEP005 Gel, 0.05% administered for two consecutive days, assessed by reflectance confocal microscopy.
- Trial name
- NCT01449513
- Testing
- Ingenol mebutate
- Where
- Germany
- Volunteers
- 24 people
- Sponsor
- LEO Pharma
Normal Pressure Hydrocephalus
Flow MRI in Normal Pressure Hydrocephalus
Normal pressure hydrocephalus diagnosis based on quantitative study of cerebro-spinal fluid and blood flow by phase contrast magnetic resonance imaging.
- Trial name
- HydroFlux (NCT01909960)
- Testing
- Flow imaging
- Where
- 2 sites in France
- Volunteers
- 144 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Solid Tumor, Adult, BRCA1 Mutation
Study of ACE-86225106 to Treat Patients With Advanced Solid Tumors
The purpose of this study is to determine if the experimental treatment with poly-ADP ribose polymerase (PARP) inhibitor, ACE-86225106 is safe, tolerable and has anti-cancer activity in adult patients with advanced solid tumors.
- Conditions
- Solid Tumor, Adult, BRCA1 Mutation, BRCA2 Mutation, Ovarian Cancer
- Trial name
- NCT06380660
- Testing
- ACE-86225106 tablet
- Where
- 14 sites in China
- Volunteers
- 298 people
- Sponsor
- Acerand Therapeutics (Shanghai) Limited
Breast Neoplasms, Neoplasm Metastasis
Efficacy and Resistant Mechanism of Eribulin and Bevacizumab for Advanced HER2 Negative Breast Cancer
This study is a prospective, multicenter, phase II randomized clinical trial. It is planned to enroll 60 patients with advanced HER2 negative breast cancer, who will be randomly assigned to the experimental group and the control…
- Conditions
- Breast Neoplasms, Neoplasm Metastasis, Drug Therapy, Bevacizumab
- Trial name
- NCT06539559
- Testing
- Eribulin, Bevacizumab
- Where
- 3 sites in China
- Volunteers
- 60 people
- Sponsor
- Wang Jiayu
Attention Deficit Hyperactivity Disorder
An Open Label Phase I/II Study of the Safety and Dopamine Transporter Binding Properties of C-11 Altropane in Normal Human Subjects and in Subjects With ADHD
The primary objective of this study is to evaluate the Binding Potential in subjects with ADHD and adults without ADHD: the intent being to demonstrate that C-11 Altropane PET can be used to differentiate adults with ADHD from…
- Trial name
- NCT00302380
- Testing
- PET imaging using C-11 altropane as the ligand.
- Volunteers
- 300 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Rheumatoid Arthritis
The Health Log: A Randomized Clinical Trial
The goal of the present study is to determine if a health management tool improves self-efficacy, satisfaction with the doctor's visit, and agreement of the statement "How satisfied are you that your concerns were addressed…
- Trial name
- NCT01913080
- Testing
- Health Log
- Where
- United States
- Volunteers
- 67 people, healthy volunteers welcome
- Sponsor
- Brigham and Women's Hospital
Breast Carcinoma, Cardiomyopathy
TRPC6 Characterization to Predict and Prevent Chemotherapy Related Cardiomyopathy and Heart Failure With Breast Cancer
This study examines TRPC6 in predicting and preventing chemotherapy related cardiac toxicity and heart failure in patients with breast cancer.
- Conditions
- Breast Carcinoma, Cardiomyopathy, Congestive Heart Failure
- Trial name
- NCT05507879
- Testing
- Biospecimen Collection, Electronic Medical Record
- Where
- 2 sites in United States
- Volunteers
- 200 people
- Sponsor
- Mayo Clinic
Normal Pregnancy
Comparative Affect of a Continuous Epidural Infusion of Clonidine During Labour. Prospective Double Blind Randomized Trial
Addition of clonidine to an epidural mixture of local anaesthetic and morphine improves analgesia and reduces the frequency of motor blockade during epidural analgesia.
- Trial name
- NCT00437996
- Testing
- Clonidine, Levobupivacaine, Sufentanil
- Where
- 2 sites in France
- Volunteers
- 85 people, healthy volunteers welcome
- Sponsor
- Hospices Civils de Lyon
Melanoma (Skin)
CP-675,206 (CTLA4-Blocking Monoclonal Antibody) Combined With Dendritic Cell Vaccine Therapy in Treating Patients With Stage III or Stage IV Melanoma That Cannot Be Removed With Surgery
RATIONALE: Biological therapies, such as CP-675,206, work in different ways to stimulate the immune system and stop tumor cells from growing. Vaccines may make the body build an immune response to kill tumor cells.
- Trial name
- NCT00090896
- Testing
- maximum tolerated dose of anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody
- Where
- United States
- Volunteers
- 18 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Malignant Melanoma
Dabrafenib and Trametinib for BRAF-inhibitor Pretreated Patients
Patients with BRAF V600 mutant advanced melanoma benefit from treatment with a BRAF-inhibitor (e.g. dabrafenib, vemurafenib) and from combination of a BRAF- and MEK-inhibitor (e.g. dabrafenib and trametinib).
- Trial name
- NCT02296996
- Testing
- Dabrafenib + Trametinib
- Where
- Belgium
- Volunteers
- 25 people
- Sponsor
- Universitair Ziekenhuis Brussel
Rheumatoid Arthritis
Rheumatoid Arthritis DMARD Intervention and UtilizationStudy
To systematically collect and document use patterns, effectiveness and safety of DMARD treatments currently used in the management of rheumatoid arthritis.
- Trial name
- NCT00116727
- Testing
- ENBREL®
- Volunteers
- 5,103 people
- Sponsor
- Amgen
Generalized Pustular Psoriasis
A Study to Test Whether Spesolimab Helps People With Generalized Pustular Psoriasis (GPP) Who Need Treatment for Repeated Flares
This study is open to adults with a serious skin disease called generalized pustular psoriasis (GPP) who have repeated flares of GPP.
- Trial name
- NCT06013969
- Testing
- Spesolimab
- Where
- 35 sites in United States, Australia and 15 more
- Volunteers
- 42 people
- Sponsor
- LEO Pharma
Metastatic Breast Cancer
Vinorelbine Oral Plus Capecitabine Combination In Metastatic Breast Cancer
This study will evaluate the toxicity and secondary the efficacy of the combination vinorelbine plus capecitabine in metastatic breast cancer patients
- Trial name
- NCT00706069
- Testing
- Vinorelbine oral, Capecitabine
- Where
- 4 sites in Greece
- Volunteers
- 40 people
- Sponsor
- Hellenic Oncology Research Group
Melanoma
A Study is to Understand the Treatment Patterns for Immunotherapy Agents and BRAF/MEK Inhibitors Used in the Treatment of Advanced Melanoma
The goal of the study is to understand the treatment patterns for immunotherapy agents and BRAF/MEK inhibitors used in the treatment of advanced melanoma
- Trial name
- NCT03696069
- Testing
- Non-Interventional
- Where
- United States
- Volunteers
- 501 people
- Sponsor
- Bristol-Myers Squibb
Epidermolysis Bullosa Dystrophica, Recessive, Epidermolysis Bullosa Dystrophica, Dominant
A Double-blind, Randomized, Intra-subject Placebo-controlled, Multicenter, Multiple Dose Study, Evaluating Safety, Proof of Mechanism, Preliminary Efficacy and Systemic Exposure in Subjects With Confirmed DDEB or RDEB Diagnosis With One or More Pathogenic Mutations in Exon 73 in the COL7A1 Gene
A double-blind, randomized, intra-subject placebo-controlled, multicenter, multiple dose study, evaluating safety, proof of mechanism, preliminary efficacy and systemic exposure in subjects with confirmed DDEB or RDEB diagnosis…
- Trial name
- NCT03605069
- Testing
- QR-313
- Where
- 6 sites in United States, France and 1 more
- Volunteers
- 2 people
- Sponsor
- Phoenicis Therapeutics
Melanoma (Skin), Skin Cancer
Adaptive BRAF-MEK Inhibitor Therapy for Advanced BRAF Mutant Melanoma
This pilot early phase I trial studies how well encorafenib, binimetinib, and nivolumab work in treating patients with BRAF mutant stage IIIC-IV melanoma.
- Conditions
- Melanoma (Skin), Skin Cancer, Skin Melanoma, Skin Carcinoma
- Trial name
- NCT03543969
- Testing
- Encorafenib, Binimetinib, Nivolumab
- Where
- United States
- Volunteers
- 14 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Lupus Nephritis
Long-Acting Tacrolimus for the Treatment of Resistant Lupus Nephritis
Glomerulonephritis is one of the major disease manifestations of systemic lupus erythematosus (SLE). Around one-third of the patients, however, do not respond to conventional immunosuppressive therapy, and they have a high risk…
- Trial name
- NCT01206569
- Testing
- Long-acting tacrolimus (Advagraf, Astellas Pharma)
- Where
- Hong Kong
- Volunteers
- 2 people
- Sponsor
- Chinese University of Hong Kong
Breast Cancer
Neoadjuvant Run-In Study With TAK-228 Followed by Letrozole/TAK-228 in Women With High-Risk ER+/HER2- Breast Cancer
Millennium has developed TAK-228, which is a novel, highly selective, orally bioavailable adenosine 5' triphosphate (ATP)-competitive inhibitor of the serine/threonine kinase referred to as the mechanistic target of rapamycin…
- Trial name
- NCT02619669
- Testing
- TAK-228, Letrozole
- Where
- United States
- Sponsor
- Gary Schwartz
Breast Cancer
Fujifilm Feature Comparison Reader Study to Compare Old vs New Processing
The purpose of the feature comparison study is to evaluate general mammographic features in images of the same breast when reconstructed with modified (ISR and DVIIm) processing as compared to the original processing (FBP with…
- Trial name
- NCT03586583
- Testing
- FBP, ISR
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- Fujifilm Medical Systems USA, Inc.
Alopecia
Hair Regrowth After Bicoronal Incision
Loss of hair growth potential in long surgical scalp incisions can become obvious to the patient and others, given hair's tendency to part along the resulting scar.
- Trial name
- NCT01557491
- Testing
- Straight Incision, Bevelled Incision
- Where
- Canada
- Volunteers
- 26 people
- Sponsor
- Sunnybrook Health Sciences Centre
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.